NCT05904236

Safety and Tolerability of Intravenous Administration of ICVB-1042

Phase 1 First-in-Human Dose Escalation and Expansion Study to Assess Safety and Tolerability of Intravenous Administration of ICVB-1042 in Patients With Advanced Solid Tumors

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 17 (actual)
• Sponsor: IconOVir Bio · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Study to evaluate the safety and tolerability of intravenous ICVB-1042

Conditions

• Patients With Advanced Solid Tumors

Interventions

Type	Name	Description
DRUG	Treatment with ICVB-1042 administered intravenously	Part A Dose Escalation to assess safety and tolerability of ascending dose levels, define the maximum tolerated dose (MTD), and expansion dose(s) Part B Dose Expansion to further assess safety and tolerability of 1 or more dose levels

Timeline

• Start date: 2023-06-01
• Primary completion: 2024-12-11
• Completion: 2024-12-20
• First posted: 2023-06-15
• Last updated: 2025-04-08

Locations

10 sites across 1 country: United States

Regulatory

• FDA-regulated drug study